REG - Frontier IP Group - Director Declaration

Frontier IPAnnouncement

26/09/2018 17:15

RNS Number : 0695C
Frontier IP Group plc
26 September 2018
 


26 September 2018
 
Frontier IP Group plc


("Frontier IP" or the "Group")
 
Director Declaration
 
Frontier IP, which specialises in commercialising university intellectual property, makes the following updated disclosures in respect of Neil Crabb, CEO of Frontier IP, pursuant to Schedule 2(g) of the AIM Rules for Companies:
 
a)            Mr Crabb was appointed as a director of B1 Medical Limited on 14 July 2006 and was a director when the company entered into compulsory liquidation on 1 November 2012. B1 Medical Limited was dissolved on 5 February 2013.
 
b)            Mr Crabb was appointed as a director of Intelligent Flow Solutions Limited on 27 March 2012 and was a director when the company entered into compulsory liquidation on 26 October 2016.
 
There are no further disclosures required pursuant to Schedule 2(g).
 
Enquiries:
 



Frontier IP Group plc


T: 0131 240 1251




Neil Crabb, Chief Executive








Andrew Johnson, Communications & Investor Relations


M: 07464 546 025




www.frontierip.co.uk


















Cenkos Securities plc (Nominated Adviser and Joint Broker)


T: 0131 220 6939




Neil McDonald / Beth McKiernan


















Peterhouse Corporate Finance Limited (Joint Broker)


T: 020 7469 0935




Lucy Williams


















Kreab (Financial PR)


T: 0207 074 1800




Robert Speed / Matthew Jervois







 
Notes to Editors:
 
Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services.
 
The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RDNMMGZLVVGGRZM